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Condensation: Women undergoing hysterectomy for endometrial cancer can expect that the 
surgery will improve their pelvic floor function at least in the short term.  
 
Short title: Pelvic floor function after hysterectomy  
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Abstract: 
Background: Pelvic floor functioning is an important concern for women requiring a 
hysterectomy for endometrial cancer. The incidence of pelvic floor symptoms has not been 
reported in women who have undergone a hysterectomy for early-stage endometrial cancer.   
Objectives: To evaluate pelvic floor function in women who have had surgical treatment for 
early stage endometrial cancer as part of the multinational Laparoscopic Approach to Cancer 
of the Endometrium (LACE) trial and to compare patients’ outcomes who had total 
abdominal total versus total laparoscopic hysterectomy.   
Study Design: Multinational, phase 3, randomized non-inferiority trial comparing disease-
free survival of patients who had total abdominal hysterectomy versus total laparoscopic 
hysterectomy. This substudy analyses the results from a self-administered validated 
questionnaire on pelvic floor symptoms (Pelvic Floor Distress Inventory (PFDI)) 
administered pre-operatively, and at follow-up visits 6, 18, 30, 42, and 54 months post-
operatively. 
Results: Overall, 381 patients with endometrial cancer were included in the analysis (total 
abdominal hysterectomy n=195; total laparoscopic hysterectomy n=186). At 6-months post-
surgery both groups experienced an improvement in Pelvic Floor Distress Inventory scores 
compared to presurgical pelvic floor wellbeing (total abdominal hysterectomy: mean change -
11.17, 95% CI: -17.11 to -5.24; total laparoscopic hysterectomy mean change -10.25, 95% 
CI: -16.31 to -4.19). The magnitude of change from baseline in pelvic floor symptoms did not 
differ between both treatment groups up to 54 months post-surgery. 
Conclusion: These findings suggest that pelvic floor function in terms of urinary, bowel and 
prolapse symptoms are unlikely to deteriorate following abdominal or laparoscopic 
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hysterectomy and are reassuring for women undergoing hysterectomy for early stage 
endometrial cancer.  
Keywords: endometrial cancer, minimally invasive hysterectomy, pelvic floor, quality of life 
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Introduction 
Endometrial cancer represents a significant health issue for women across the world. An 
estimated 300,000 women were diagnosed with endometrial cancer in 2012 and its incidence 
is still rising.1 Advanced age, and an oversupply of endogenous or exogenous oestrogen are 
the most common and well established risk factors for endometrial cancer. Patients often 
have comorbidities such as obesity, diabetes mellitus and hypertension.2-5 Treatment of 
endometrial cancer is primarily surgical and open, abdominal surgery should generally be 
avoided because its association with increased treatment-related morbidity at comparable 
survival outcomes.6-8   
Urinary incontinence, pelvic organ prolapse and bowel dysfunction are common conditions 
following childbirth and the incidence of symptoms increases with age, the number of vaginal 
deliveries and obesity.9, 10 These conditions significantly impact on women’s quality of life, 
have considerable financial implications and contribute to health care utilization, personal 
and health care costs.11, 12 Previous studies on urinary function in gynecological cancer 
patients have shown a decline in function following cancer treatment.13-15 However, these 
studies analyzed pelvic floor outcomes of very diverse groups of patients who had treatment 
for cervical and endometrial cancer, who required simple or radical hysterectomies and even 
included patients who received definitive pelvic radiotherapy. It was concluded that women 
with early-stage endometrial cancer undergoing either total abdominal hysterectomy (TAH) 
or total laparoscopic hysterectomy (TLH) had better pelvic floor functional outcomes 
compared to those who required more aggressive cancer treatment.13-16 Data on which these 
conclusions have been placed is limited, and confirmation in larger studies of early stage 
endometrial cancer patients is required to advise the ever increasing number of patients of the 
expectations with respect to pelvic floor function after surgery. 
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The aim of the present study was to evaluate pelvic floor function in a large cohort of women 
receiving surgical treatment for early stage endometrial cancer as part of the multinational 
Laparoscopic Approach to Cancer of the Endometrium (LACE) trial and to compare 
outcomes of patients who had TAH versus TLH.  
Materials and Methods  
Study design and procedures 
The LACE trial was a multinational randomized, phase 3 clinical trial comparing total 
abdominal hysterectomy (TAH) to total laparoscopic hysterectomy (TLH) in women with 
apparent Stage 1 endometrial cancer (EC).  All patients also had a bilateral salpingectomy 
and oophorectomy. A total of 760 patients were recruited through 20 gynecological cancer 
centres in Australia, New Zealand, and Hong Kong. Ethics approval was obtained from each 
hospital’s Human Research and Ethics Committees. The lead Human Research Ethics (HRE) 
Committee was the Royal Brisbane & Women's Hospital HRE Committee (approval number: 
EC00172 -  20 September 2004). Written informed consent was obtained from patients prior 
to randomization. Quality of Life (QoL) outcomes17, incidence and risk factors for adverse 
events7, 18 and recurrence and survival data6 of the LACE trial have been previously reported. 
Eligibility and exclusion criteria were described in detail previously.19 In brief; patients with 
histologically confirmed endometrial adenocarcinoma of any FIGO grade without evidence 
of extra-uterine disease by imaging (computed tomography (CT) or Magnetic Resonance 
Imaging (MRI) of the abdomen and pelvis and chest radiograph or chest CT) were eligible. 
Women with a histological cell-type other than endometrioid on curettage, clinically 
advanced disease (stage II – IV using FIGO 2009 criteria for stage or bulky lymph nodes on 
imaging), or uterine size greater than 10 weeks of gestation were ineligible.  
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Patient-related assessments were collected prior to surgery, at week 1, and months 1, 3, and 6, 
post-surgery. All patients were followed up at 12 months post-surgery and then annually for 
survival outcomes. Patients without events were censored at the date of data lock (3rd March 
2016) or date of last contact for patients lost to follow up. Randomization procedures were 
also described in detail previously.6 
The surgical procedures and their steps have been described in detail earlier.19 For the TLH 
an anatomically curved silicone tube with a proximal airtight cap that prevents loss of 
pneumoperitoneum, enables instrument access and facilitates the safe removal of specimens 
transvaginally was used (McCartney TubeTM, The O.R. Company, Melbourne, Australia). 
TAH was performed through a vertical midline or lower transverse incision.  
Histopathological findings were used to determine the need for adjuvant treatment according 
to local institutional clinical practice guidelines, and typically were discussed in 
multidisciplinary meetings. The delivery and management of radiation therapy or 
chemotherapy was carried out according to local institutional clinical practice guidelines. 
Data on dosimetry or chemotherapy dosing was recorded. 
All clinical Adverse Events (AEs) encountered during the clinical study were documented. 
The intensity of AEs was graded using the National Cancer Institute Common Terminology 
Criteria for Adverse Events version 3.0 (CTC-AE v3.0). The incidence of, and risk factors 
for, AEs was reported previously.7, 18  
For quality assurance of the surgical intervention, a rigorous accreditation process was 
followed as described in detail previously.19 Surgeons were required to (i) be certified 
gynecological oncologists proficient in TAH and TLH or under the direct supervision of a 
certified gynecological oncologist in theatre; and (ii) had to be accredited by the LACE trial 
committee after they provided evidence of surgical proficiency.  
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Outcomes 
While the primary outcome of the LACE trial was disease-free survival (DFS) at 4.5 years, 
for this substudy, the outcome of interest was pelvic floor symptoms; a pre-specified 
secondary outcome measured using the Pelvic Floor Distress Inventory (PFDI). The PFDI 
was only introduced after approximately half of the patients had already been enrolled in the 
study and only collected for patients enrolled in the latter (n=381) part of the trial. This 
sample size was sufficient to provide 80% power to detect a difference between the two 
groups of at least 15 points or more (one standard deviation (SD)) in the PFDI summary 
score. Previous work has identified that a PFDI summary score of 13.5 or more reflects a 
minimally important change among women with mild to moderate pelvic floor symptoms.20 
The PFDI21 is a 20-item questionnaire consisting of three domains; the 6-item pelvic organ 
prolapse distress inventory (POPDI-6), the 8-item colorectal-anal distress inventory (CRADI-
8) and the 6-item urinary distress inventory (UDI-6). Item response values ranged from 0-4. 
Following the PFDI scoring instructions, the mean score from the items in each subscale was 
multiplied by 25 to provide a common range for the subscales (range 0-100), the overall 
PFDI score was the summation of the subscale scores (range 0-300). A higher score signifies 
worse pelvic floor wellbeing. The PFDI provides a standardized and reproducible assessment 
of symptom severity and pelvic floor wellbeing changes in women with pelvic floor 
disorders. It has been reported to have good test-retest reliability, internal consistency and in 
external validation was found to be sensitive to change.22 Use of this psychometrically robust 
self-administered questionnaire is a valid way of measuring the presence, severity, and 
impact of a symptom or condition on a patient’s activities and well-being. The PFDI was 
administered pre-operatively, then at follow-up visits 6, 18, 30, 42 and 54 months post-
operatively.  
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Statistical Analysis 
All statistical analyses were conducted according to the intention-to-treat (ITT) principle.  
The number of completed questionnaires at each time point was summarized. Patients who 
had not completed the PFDI pre-operatively were excluded from analysis. Incomplete 
questionnaires were excluded when analysing the PFDI total score; when analysing the 
domains separately, those domains which were completed fully were included in the analysis 
even if the remainder of the questionnaire was incomplete.  
Patient demographic and clinical characteristics are presented as frequency (%) if categorical 
and mean (SD) if continuous. Pelvic floor scores (total and sub-domains) were summarized 
as mean (SD) at each time point by randomization group.  Plots were constructed to 
graphically visualize the mean scores (with corresponding 95% confidence interval) over 
time for the total score and each of the pelvic organ prolapse, colorectal-anal and urinary 
distress inventory domains. In addition, a patient was considered to have pelvic floor 
symptoms if they answered ‘moderate’ or ‘severe’ for at least one of the PFDI questions and 
the proportion of patients with pelvic floor symptoms was summarised at each time point.  
At each time point, differences from baseline for each outcome were calculated and these 
differences analysed using the repeated measure method of generalised estimating equations 
(GEEs) (which account for correlated outcomes and can account for missing data, retaining 
all available observations in the models). Additionally, time-by-treatment interaction terms 
were fitted to estimate the change in scores from baseline to each time point and to determine 
whether these changes differed between the treatment groups. This approach takes into 
account the within-patient correlation that occurs in the scores, using an exchangeable 
correlation structure for the robust variance estimation. As pelvic floor wellbeing of patients 
overall was good, the analyses then specifically focussed on women who reported at least one 
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or more moderate to severe pelvic floor symptoms on any of the questionnaire items. The 
proportion of women at each timepoint was summarised. Stratified analyses then reported 
whether women had pelvic floor issues already before surgery or developed new pelvic floor 
issues after surgery, and whether these resolved or remained at subsequent timepoints. The 
proportion of women with pelvic floor symptoms was also assessed depending on whether or 
not adjuvant therapy was received. 
All analyses were conducted in SAS version 9.3 (SAS Institute, Inc, Cary, NC) and STATA 
version 14.1 (Statacorp, Texas) with significance testing at at the 5% level (two-sided) . No 
statistical adjustments to the analysis were made for multiple testing or to account for missing 
data. 
Results 
Of the 760 patients randomized into the LACE trial, 381 patients completed the PFDI 
questionnaire pre-operatively and at least one follow-up PFDI questionnaire. Of these, 195 
patients were in the total abdominal hysterectomy (TAH) group with 186 patients in the total 
laparoscopic hysterectomy (TLH) group (Figure 1). 
Baseline characteristics were similar between randomization groups (Table 1). Demographic 
and clinical characteristics were representative of the overall LACE population 
(Supplementary Table 1).  
Pre-operatively, of the 381 participating patients, 322 (85%) patients provided a complete 
PFDI response with all three subscales answered . By 54 months post-op, participation had 
dropped to 207 (54%) due to death and/or disease progression (n=41, 24%), 88 (51%) 
patients had not been followed up to the 54-month timepoint and the remaining 45 (26%) did 
not complete their questionnaire at the 54-month time point. For the individual scales, the 
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pelvic organ prolapse domain had the highest completion rate (92-97% over time) while the 
colorectal-anal distress subscale had the lowest rate (89-94%) (Supplementary Table2). 
Summary of PFDI scores over time  
Figures 2A-D show the mean scores (with 95% CI around the mean) for PFDI and domains at 
the pre-specified time points, according to treatment group. Within both treatment groups, 
there was an initial improvement in pelvic floor function 6-months post-surgery primarily due 
to pelvic organ prolapse, and urinary distress domains. Patients in the TLH group consistently 
had a lower pelvic floor functioning score indicating better wellbeing, which was most 
pronounced in the urinary distress domain, but the difference between the TAH and TLH 
group scores was not statistically significant. 
Change in PFDI scores over time 
The results from the GEE models assessing the difference in change from baseline between 
the TLH and TAH groups are presented as a forest plot in Figure 3 (and supplementary Table 
4). For all the models, the interaction between treatment and time was not statistically 
significant, suggesting that the change in PFDI over time did not differ between the 
randomization groups. At 6-months post-surgery both treatment groups experienced an 
improvement in total PFDI score (TAH: mean change -11.17, 95% CI: -17.11 to -5.24; TLH 
mean change -10.25, 95% CI: -16.31 to -4.19). However, there was no evidence of a 
significant difference between the treatment groups over time in terms of change from 
baseline PFDI scores with confidence intervals all overlapping the zero (Figure 3).  
Patients in both the TAH and TLH groups showed an improvement from baseline in the 
pelvic organ prolapse domain at each time point; however there was no evidence to support a 
difference between the two treatment groups in change in the pelvic organ prolapse 
symptoms (interaction p-value = 0.79). Similarly, both treatment groups showed an 
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improvement at 6 months post-surgery in the urinary distress domain (TAH change -4.60, 
95% CI: -7.47 to – 1.79; TLH mean change -4.19, 95% CI: -7.12 to -1.26; Figure 3). There 
were no significant changes in the colorectal-anal distress domain over time or between 
treatment groups.   
Although the proportion of patients with at least one moderate to severe pelvic floor problem 
was higher in the TAH group overall, and in the pelvic organ prolapse and urinary distress 
domains across most postsurgical time points, the difference in the proportions of women in 
the TAH or TLH groups who reported at least one symptom was small (about 3-5%) (Table 
2). The stratified summary of patients shows that 30% in both groups had no moderate to 
severe symptoms at baseline and throughout the study observation period, 43% of patients in 
the TAH and 48% of patients in the TLH group had one or more moderate to severe symptom 
at baseline, and 24% of patients in the TAH group, and 19% in the TLH group developed one 
or more moderate to severe new symptoms after baseline. Of those women reporting either 
existing or new symptoms about half resolved and half persisted in both treatment groups 
(Table 3). There was no difference in persisting or new pelvic floor symptoms between 
women who did or did not receive adjuvant therapy (Supplementary Table 3). 
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Comment 
This study provides some answers to questions commonly asked by patients who require 
surgery for endometrial cancer about how their symptoms of urinary incontinence, pelvic 
organ prolapse and bowel dysfunction may progress. Women in both groups improved 
initially and their scores then slowly declined while maintaining some beneficial gains 
compared to their pre-surgical pelvic floor wellbeing. The data also reported here show that 
there was no difference between TLH and TAH with respect to pelvic floor symptoms for up 
to 54 months post-surgery. These findings will reassure for women undergoing hysterectomy 
for endometrial cancer, either by TAH or TLH. 
The data provided here have been obtained through a prospective, randomised trial using a 
validated questionnaire that was completed by patients prior to surgery and up to 54 months 
post-surgery at multiple time points. Recently, the results of three randomised controlled 
clinical trials were published suggesting that TLH is superior to TAH in regards to short-term 
outcomes and equivalent with respect to survival outcomes.6, 8, 23 The data reported here 
provides additional empirical evidence by demonstrating that women who receive TLH will 
have similar outcomes compared to women treated by TAH with respect to pelvic floor 
functioning. 
Our findings extend previous studies by directly comparing two approaches to total 
hysterectomy in a homogenous group of patients with early endometrial cancer. Previous 
studies on the pelvic floor function after hysterectomy have mainly enrolled women with 
benign indications, or concentrated on the differences in outcomes between total and subtotal 
hysterectomy. A Cochrane review comparing those two techniques found no difference in 
regards to urinary incontinence, bowel function or sexual function.24 However, comparing 
pre- and post- hysterectomy scores, there was an overall improvement in symptoms of 
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urinary incontinence post-hysterectomy noted in that review for both total and subtotal 
hysterectomy.  The only previous study assessing bowel function found no difference pre- or 
post-operatively between the different routes of hysterectomy, and no changes over time.25 
Sexual function was also not found to be different between the different hysterectomy 
techniques, with a trend towards improvement post-operatively.24 Subsequently, another 
Cochrane review specifically examining the impact of route of hysterectomy for benign 
conditions noted an absence of high-quality data on urinary, bowel, sexual function and 
quality of life and suggested the collection of long-term data for all of these patient reported 
outcomes.26 
The importance of using data from prospective studies when examining pelvic floor function 
and quality of life has been acknowledged by clinicians and women alike.  Previously, the 
perception of deterioration of pelvic floor function has been related to women dating the 
onset of their symptoms to a significant life event (e.g. a hysterectomy).27 However, this 
concern has been not be confirmed by prospective studies on hysterectomy for benign 
conditions.24, 25 Women in the present study had, on average, good pelvic floor functioning, 
and the average score did not change significantly after surgery in either group. The present 
study now provides evidence for women who require a hysterectomy for early-stage 
endometrial cancer, and who have one or more moderate to severe symptom before surgery, 
that at least half can expect a resolution of those symptoms.  
Previous studies on women who require hysterectomy for cervical or endometrial cancer have 
found an increase in urinary and bowel dysfunction secondary to radical hysterectomy and 
adjuvant pelvic radiation therapy being associated with more severe urinary and bowel 
symptoms, and impact on quality of life.13-15 In contrast, most patients on the LACE trial had 
a Piver Type 1 hysterectomy and pelvic floor function, in terms of urinary, bowel and 
prolapse symptoms, did not deteriorate. This could point to the possibility that pelvic floor 
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symptoms experienced by women after gynecological cancer in previous studies may arise as 
a cause of nerve damage inflicted by radical hysterectomy with or without postoperative 
radiation treatment, rather than a standard Piver Type 1 hysterectomy.28-30 
In conclusion, this study adds to the understanding of pelvic floor function for women 
following hysterectomy, particularly after an endometrial cancer diagnosis, with reassurance 
that their function is unlikely to deteriorate after surgery with Piver Type I hysterectomy for 
endometrial cancer. Our study addresses some of previously raised research questions and 
provides answers for clinicians and women on what they can expected following either open 
or laparoscopic hysterectomy for stage 1 endometrial cancer. This should aid in the 
counselling process prior to hysterectomy via open or laparoscopic routes. 
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Table 1: Sociodemographic and clinical characteristics summarised by randomised 
treatment group 
 
TAH 
(N=195) 
TLH 
 (N=186) 
Age in years, mean (SD) 62.6 (10.9) 63.0 (9.5) 
BMI Category   
Normal (<25kg/m2)  26 (13) 21 (11) 
Overweight (25-29.99 kg/m2)  42 (22) 47 (25) 
Obesity class I (30-34.99 kg/m2) 41 (21) 34 (18) 
Obesity class II (35-39.99 kg/m2) 35 (18) 39 (21) 
Obesity class III (≥40 kg/m2) 44 (23) 41 (22) 
Missing 7 (4) 4 (2) 
   
Education   
Completed 12 years of school or less 126 (65) 115 (62) 
Completed > 12 years of school 64 (33) 69 (37) 
Missing 5 (3) 2 (1) 
Employment   
Employed full-time 21 (11) 32 (17) 
Employed part-time or casual 33 (17) 21 (11) 
Retired 75 (38) 77 (41) 
Other 61 (31) 54 (29) 
Missing 5 (3) 2 (1) 
Marital status   
Partnered 121 (62) 112 (60) 
Not partnered 69 (35) 72 (39) 
Missing 5 (3) 2 (1) 
Private health insurance   
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TAH 
(N=195) 
TLH 
 (N=186) 
No 142 (73) 130 (70) 
Yes 48 (25) 54 (29) 
Missing 5 (3) 2 (1) 
Household Income   
AU$40,000+ 49 (25) 46 (25) 
Less than AU$40,000 118 (61) 118 (63) 
Missing 5 (3) 2 (1) 
Birth country   
Australia 121 (62) 113 (61) 
Other 69 (35) 71 (38) 
Not answered 23 (12) 20 (11) 
Missing 5 (3) 2 (1) 
ECOG status   
0 168 (86) 168 (90) 
1 27 (14) 18 (10) 
PFDI† at Baseline (/300)*   
N 194 186 
Mean(SD) 44.5 (44.6) 38.2 (38.7) 
PFDI† at Baseline (/300) 
(completed) 
  
N 165 157 
Mean(SD) 40.2 (42.4)) 38.2 (38.7) 
Pelvic Floor issues††   
N (%) 83 (43) 90 (48) 
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Abbreviations: TAH=Total Abdominal Hysterectomy; TLH=Total Laparoscopic 
Hysterectomy, PFDI Pelvic Floor Distress inventory 
* Estimate includes incomplete questionnaires  
†PFDI score calculated as 25*(score/number of questions answered) 
†† defined as reporting at least one or more symptom of moderate or severe extent 
n (%) presented unless otherwise indicated 
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Table 2: The number (%) of patients with pelvic floor problems defined as at least one 
symptom of moderate of severe severity for any item within the total score combining 
the three subscales and each scale individually 
PFDI Scale  Pre-op 
(n = 381) 
6 months 
post-op 
(n = 320) 
18 
month 
FU 
(n = 291) 
30 
month 
FU 
(n = 274) 
42 
month 
FU 
(n = 227) 
54 
month 
FU 
(n = 207) 
PFDI (Total): 
 
TAH 56 (29%) 34 (21%) 32 (21%) 31 (22%) 25 (22%) 24 (24%) 
TLH 43 (23%) 21 (13%) 31 (22%) 21 (16%) 13 (12%) 12 (11%) 
POPDI-6 
(only) 
TAH 9 (5%) 4 (2%) 7 (5%) 0 2 (2%) 2 (2%) 
TLH 14 (8%) 4 (3%) 0 2 (1%) 5 (4%) 2 (2%) 
CRADI-8 
(only) 
TAH 7 (4%) 9 (5%) 9 (6%) 9 (6%) 7 (6%) 1 (1%) 
TLH 13 (7%) 7 (4%) 10 (7%) 11 (8%) 9 (8%) 9 (8%) 
UDI-6 
(only) 
TAH 11 (6%) 8 (5%) 11 (7%) 7 (5%) 7 (6%) 10 (10%) 
TLH 20 (11%) 10 (6%) 9 (6%) 11 (8%) 14 (13%) 8 (8%) 
 
 
 
 
 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
27 
 
Table 3: Proportion of participants who experienced at least one moderate to severe symptom 
grouped by stable, resolved or unresolved symptom burden over the course of the study 
Outcome of PFDI symptoms   
Total Abdominal 
Hysterectomy 
(n=195) 
Total Laparoscopic 
Hysterectomy 
(n=186) 
No symptoms throughout the 
observation period: 
 59 (30%) 56 (30%) 
Baseline symptoms   83 (43%) 90 (48%) 
 Resolved  38 (19%) 38 (20%) 
 Unresolved 39 (20%) 44 (24%) 
 Unknown 6 (3%) 8 (4%) 
New symptoms   46 (24%) 36 (19%) 
 Resolved 17 (9%) 17 (9%) 
 Unresolved  29 (15%) 19 (10%) 
Unknown*  7 (4%) 4 (2%) 
    
Abbreviations: PFDI Pelvic Floor Distress inventory; **patients with no symptoms at 
baseline who only answered the baseline questionnaire 
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Figure Captions 
Figure 1: Participant Flow 
Figure 2: Total PFDI and domain scores over time by treatment group (mean score with 95% 
CI).  
Figure 3: Forest plot of the GEE estimates for the mean difference (95% CI) in pelvic floor 
wellbeing scores from baseline between the TAH and TLH group. 
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Supp Table 1: Baseline patient characteristics summarised by treatment group 
 
Total Abdominal 
Hysterectomy 
(N=353) 
Total Laparoscopic 
Hysterectomy 
(N=407) 
Total Abdominal 
Hysterectomy 
(N=195) 
Total Laparoscopic 
Hysterectomy 
(N=186) 
Age in years, mean (SD) 63.1 (10.6) 63.3 (10.0) 62.6 (10.9) 63.0 (9.5) 
ECOG status     
0 303 (86%) 352 (86%) 168 (86%) 168 (90%) 
1 50 (14%) 55 (14%) 27 (14%) 18 (10%) 
Grade of Differentiation     
Grade 1 (Well differentiated) 223 (63%) 259 (64%) 125 (64%) 115 (62%) 
Grade 2 (Moderately differentiated) 107 (30%) 120 (29%) 53 (27%) 54 (29%) 
Grade 3 (Poorly differentiated) 23 (7%) 28 (7%) 17 (9%) 17 (9%) 
Surgical Stage     
Missing 3 (1%) 4 (1%) 1 (1%) 1 (1%) 
I   1 (1%)  
IA 237 (67%) 286 (70%) 130 (67%) 131 (70%) 
IB 44 (12%) 55 (14%) 20 (10%) 23 (12%) 
II 45 (13%) 32 (8%) 27 (14%) 15 (8%) 
IIIA 4 (1%) 11 (3%) 3 (2%) 5 (3%) 
IIIB 1 (<1%) 4 (1%) 1 (1%) 2 (1%) 
IIIC1 12 (3%) 11 (3%) 7 (4%) 9 (5%) 
IIIC2 3 (1%) 1 (<1%) 1 (1%)  
IVA 1 (<1%) 0 (<1%) 1 (1%)  
IVB 3 (1%) 3 (1%) 3 (2%)  
Node dissection performed     
Yes 147 (42%) 246 (60%) 112 (57%) 79 (42%) 
No 206 (58%) 161 (40%) 83 (43%) 107 (58%) 
Adjuvant Therapy     
None 261 (74%) 336 (83%) 133 (68%) 137 (74%) 
Chemotherapy or radiation (or both) 92 (26%) 71 (17%) 62 (32%) 49 (26%) 
Hospital Stay     
≤2 days   3 (2%) 128 (69%) 
>2 days   192 (98%) 58 (31%) 
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Supp table 2: Number of questionnaires and PFDI scales completed at each visit (n=381) 
 
Pre-op 
Post-operative follow up months 
 6 18 30 42 54 
Completed questionnaires 
a,b
 381 (100) 320 (84) 291 (76) 274 (72) 227 (60) 207 (54) 
Completed scales 
c
       
Pelvic Floor Distress Inventory (PFDI) 322 (85) 286 (89) 259 (89) 234 (85) 184 (81) 172 (83) 
Pelvic organ prolapse (POPDI-6) 369 (97) 307 (96) 278 (96) 260 (95) 210 (93) 190 (92) 
Colorectal-Anal (CRADI-8) 344 (90) 302 (94) 270 (93) 250 (91) 202 (89) 184 (89) 
Urinary (UDI-6) 361 (95) 304 (95) 272 (93) 255 (93) 203 (89) 188 (91) 
n (%) presented 
a
 Includes both fully and partially completed questionnaires 
b
 Pre-op number used as the denominator for the row percentages 
c
 Percentages expressed a column percent for the time period count of completed questionnaires 
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Supp table 3: Summary of moderate/severe PFDI symptom outcomes during the study by adjuvant 
treatment 
Outcome of PFDI symptoms   
Adjuvant therapy* 
(n=111) 
No adjuvant therapy 
(n=270) 
No symptoms: 
 
 35 (32%) 80 (30%) 
Baseline symptoms   49 (44%) 124 (46%) 
 Resolved  22 (20%) 54 (20%) 
 Unresolved 25 (23%) 58 (21%) 
 Unknown 2 (1%) 12 (4%) 
New symptoms   27 (24%) 66 (24%) 
 Resolved 12 (11%) 22 (8%) 
 Unresolved  13 (12%) 35 (13%) 
Unknown  2 (4%) 9 (3%) 
*commencement of adjuvant therapy varied on a patient basis depending on surgical outcome and progression, therefore, 
PFDI outcomes may not coincide with adjuvant therapy 
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Supp table 4: Results from the GEE modelling, including a time-by-randomisation group interaction term 
alongside main effects 
PFDI POPDI CRADI UDI 
Model Estimate 
(95% CI) p-value 
Model Estimate 
(95% CI) p-value 
Model Estimate 
(95% CI) p-value 
Model Estimate 
(95% CI) p-value 
TLH vs. TAH 0.92 (-7.56, 9.41) 0.83 0.41 (-3.69, 4.51) 0.84 -0.43 (-3.43, 2.56) 0.78 1.03 (-2.27, 4.33) 0.54 
Visit 0.12 0.02 0.09 0.89 
18 Month FU 4.88 (-0.49, 10.25) 3.36 (0.65, 6.07) 1.30 (-0.70, 3.31) 0.33 (-1.67, 2.34) 
30 Month FU 7.06 (1.49, 12.63) 3.10 (0.30, 5.90) 3.01 (0.93, 5.09) 0.98 (-1.10, 3.06) 
42 Month FU 4.96 (-1.01, 10.93) 3.59 (0.58, 6.59) 1.76 (-0.47, 3.99) -0.08 (-2.33, 2.17) 
54 Month FU 5.71 (-0.45, 11.87) 4.63 (1.52, 7.74) 1.43 (-0.88, 3.74) 0.41 (-1.90, 2.72) 
Treatment-by-Time 0.82 0.79 0.42 0.79 
18 Month FU 1.77 (-5.96, 9.49) -0.19 (-4.08, 3.70) 1.06 (-1.83, 3.94) 0.81 (-2.08, 3.69) 
30 Month FU -2.04 (-9.98, 5.91) 0.28 (-3.71, 4.28) -1.91 (-4.87, 1.06) -0.45 (-3.41, 2.52) 
42 Month FU -1.13 (-9.60, 7.34) -1.67 (-5.94, 2.59) -0.06 (-3.22, 3.10) 0.53 (-2.66, 3.72) 
54 Month FU -3.22 (-11.93, 5.49) -2.06 (-6.45, 2.33) -0.68 (-3.94, 2.58) -1.15 (-4.42, 2.11) 
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Supp table 5: Results from the GEE modelling, including a time-by-randomisation group interaction term 
alongside main effects and adjusting for known prognostic variables 
PFDI POPDI CRADI UDI 
Model Estimate 
(95% CI) p-value 
Model Estimate 
(95% CI) p-value 
Model Estimate 
(95% CI) 
p-
value 
Model Estimate 
(95% CI) 
p-
value 
TLH vs. TAH 1.1 (-7.53, 9.72) 0.80 -0.38 (-3.39, 2.63) 0.80 0.14 (-4.04, 4.32) 0.95 1.37 (-1.95, 4.69) 0.42 
Visit  0.14  0.10  0.04  0.81 
18 Month FU 5.18 (-0.23, 10.6)  1.16 (-0.84, 3.16)  3.63 (0.89, 6.36)  0.53 (-1.52, 2.59)  
30 Month FU 7.02 (1.40, 12.65)  2.93 (0.86, 5.00)  2.99 (0.16, 5.83)  1.13 (-1.00, 3.26)  
42 Month FU 4.77 (-1.24, 10.78)  1.6 (-0.62, 3.82)  3.49 (0.46, 6.51)  0.01 (-2.29, 2.30)  
54 Month FU 5.05 (-1.15, 11.25)  1.39 (-0.9, 3.69)  4.11 (0.98, 7.24)  0.35 (-2.01, 2.70)  
Treatment-by-Time  0.89  0.44  0.78  0.85 
18 Month FU 1.15 (-6.61, 8.92)  1.11 (-1.76, 3.97)  -0.52 (-4.43, 3.39)  0.45 (-2.49, 3.39)  
30 Month FU -1.85 (-9.84, 6.14)  -1.73 (-4.67, 1.22)  0.42 (-3.60, 4.44)  -0.56 (-3.59, 2.46)  
42 Month FU -1.11 (-9.62, 7.41)  0.21 (-2.93, 3.35)  -1.86 (-6.15, 2.44)  0.47 (-2.78, 3.72)  
54 Month FU -3.25 (-12, 5.50)  -0.68 (-3.91, 2.55)  -1.89 (-6.31, 2.52)  -1.38 (-4.71, 1.95)  
         
Age (≥65 vs. <65) -2.79 (-10.33, 4.74) 0.47 -1.65 (-4.21, 0.92) 0.21 -0.19 (-3.78, 3.41) 0.92 -0.84 (-3.76, 2.07)  
BMI (≥30 vs. < 30) 5.82 (-1.87, 13.52) 0.14 1.17 (-1.44, 3.79) 0.38 2.37 (-1.30, 6.04) 0.21 2.28 (-0.70, 5.26)  
ECOG (1 vs. 0) -2.85 (-14.62, 8.91) 0.64 1.3 (-2.71, 5.30) 0.53 -2.68 (-8.30, 2.93) 0.35 -1.72 (-6.28, 2.83)  
History of malignancy  6.35 (-6.78, 19.48) 0.34 1.77 (-2.7, 6.24) 0.44 1.58 (-4.69, 7.84) 0.62 2.99 (-2.09, 8.08)  
Node dissection  -2.02 (-9.91, 5.87) 0.62 -1.72 (-4.41, 0.97) 0.21 -1.34 (-5.10, 2.43) 0.49 0.82 (-2.23, 3.88)  
Surgical stage  0.26  0.34  0.03   
2 vs. 1 -7.7 (-19.63, 4.24)  3.03 (-1.04, 7.1)  -7.58 (-13.28, -1.88)  -3.21 (-7.83, 1.40)  
3 or 4 vs. 1 -8.54 (-22.25, 5.16)  0.99 (-3.68, 5.66)  -0.24 (-6.78, 6.30)  -9.38 (-14.68, -4.08)  
Differentiation  0.99  0.92  0.78   
2 vs. 1 -0.39 (-8.92, 8.14)  0.07 (-2.84, 2.97)  1.39 (-2.69, 5.46)  -1.55 (-4.87, 1.76)  
3 vs. 1 0.58 (-11.6, 12.75)  -0.8 (-4.95, 3.35)  1.35 (-4.46, 7.16)  0.26 (-4.45, 4.97)  
 
